ENDV
Endonovo Therapeutics, Inc.Company with tickers: ENDV
Income-statement, balance-sheet and cash-flow figures extracted from the company's SEC filings — 10-K annual and 10-Q quarterly reports — and standardised for comparison across periods.
| Line Item | Value | Unit | Period End | Form | Filed |
|---|---|---|---|---|---|
| Revenue | — | ||||
| Revenue (ASC 606) | $1,520 | USD | 2023-09-30 | 10-Q | 2023-12-29 |
| Cost of Revenue | $827 | USD | 2023-09-30 | 10-Q | 2023-12-29 |
| Gross Profit | $693 | USD | 2023-09-30 | 10-Q | 2023-12-29 |
| Operating Expenses | $473,490 | USD | 2023-09-30 | 10-Q | 2023-12-29 |
| Research & Development | — | ||||
| Operating Income | $-472,797 | USD | 2023-09-30 | 10-Q | 2023-12-29 |
| Net Income | $-766,170 | USD | 2023-09-30 | 10-Q | 2023-12-29 |
| EPS (Basic) | $0.00 | USD/shares | 2023-09-30 | 10-Q | 2023-12-29 |
| EPS (Diluted) | $0.00 | USD/shares | 2023-09-30 | 10-Q | 2023-12-29 |
Revenue Breakdown
Annual revenue as the company disaggregates it in its own XBRL filings. Years a component wasn't reported show a dash.
By Product & Service (USD)
| Component | 2020-12-31 | 2021-12-31 | 2022-12-31 |
|---|---|---|---|
| Royalty | — | — | $113,623 |
| Direct Sales Medical Care Providers Gross | $165,796 | $73,105 | $21,732 |